TPU-006

About TPU-006

Teikoku is developing a first in class 3-day patch for chronic pain management which may become best in class. More details to be disclosed soon.

Advantages of TPU-006

  • Extended pain management
  • NOT a controlled substance (Non-Narcotic)  
  • Easy to prescribe
  • Reduce opioid ose: abuse issues, side effects (e.g. constipation)
  • Non NSAID

About Pain Management

The global pain management therapeutics market has huge potential for growth due to the large population that is affected by medically significant pain. The market is growing at a moderate growth rate, driven by the cancer pain, low back pain and post-operative pain relief markets. In 2010, the global pain management therapeutics market was estimated at $28.6 billion, representing a CAGR of 5.3% between 2002 and 2010. The post-operative pain relief market, with sales of $5.9 billion in 2010, accounted for one fifth of the total pain management therapeutics market. The low back pain market, with sales of $4.9 billion, was the second largest market segment, with a share of 17% of the worldwide pain management therapeutics market. The low back pain market is followed by the cancer pain and neuropathic pain relief markets, accounting for 16% each of the global pain management therapeutics market.

The global pain management market is driven by anticonvulsant Lyrica and anti-depressant Cymbalta, which are expected to expire in 2013. By 2017, the global pain management therapeutics market is forecast to generate sales of $35.1 billion, representing a CAGR of 3.0% between 2010 and 2017

Source: BCC Research